Cytokinetics Announces $800 Million Public Offering of Common Stock Priced at $60 Per Share

Cytokinetics Incorporated recently announced the pricing of an upsized public offering of its common stock. The offering involves a total of 13,333,334 shares of common stock, priced at $60.00 per share. As a result, the gross proceeds to Cytokinetics from this offering are expected to be approximately $800 million, before deducting underwriting discounts and commissions, and other offering expenses.

The company has also granted the underwriters a 30-day option to purchase up to an additional 2,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 9, 2026, subject to customary closing conditions. J.P. Morgan, Goldman Sachs & Co. LLC, and Jefferies are acting as joint book-running managers for the offering.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 7, 2026

Author

GOAI